Related references
Note: Only part of the references are listed.Study suggests by that limitations of HAART can be explained genetic differences at two human loci
[Anonymous]
FUTURE VIROLOGY (2008)
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals
Sunil K. Ahuja et al.
NATURE MEDICINE (2008)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Roy M. Gulick et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
Adriano Lazzarin et al.
LANCET (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Jose Valdez Madruga et al.
LANCET (2007)
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients
Richard Haubrich et al.
AIDS (2007)
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
Christine Katlama et al.
AIDS (2007)
InHIV-1 pathogenesis the die is cast during primary infection
Mireille Centlivre et al.
AIDS (2007)
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial
Joseph Gathe et al.
CLINICAL INFECTIOUS DISEASES (2006)
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients:: 24-week results of the RESIST-2 trial
Pedro Cahn et al.
CLINICAL INFECTIOUS DISEASES (2006)
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults
John A. Bartlett et al.
AIDS (2006)
CCL5-CCR5-mediated apoptosis in T cells - Requirement for glycosaminoglycan binding and CCL5 aggregation
Thomas T. Murooka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384
Rajesh T. Gandhi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
HIV-1 coreceptor use in triple-class treatment experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response
Tom Melby et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression
JA LaBonte et al.
JOURNAL OF VIROLOGY (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
A Lazzarin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy
PW Hunt et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells
A Algeciras-Schimnich et al.
AIDS (2002)
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
S Grabar et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
